At the 2026 ASCO Annual Meeting, Boehringer Ingelheim presented new data from across its oncology clinical development program, including patient-reported outcomes (PROs) for HERNEXEOS® (zongertinib tablets) in HER2… read more.
Incyte announced final 24-week data from the Phase 3 TRuE-AD4 study evaluating the efficacy and safety of Opzelura (ruxolitinib) cream in adults with moderate atopic dermatitis (AD) who had an… read more.
U.S. teens report far less anabolic steroid use than they did two decades ago, but creatine use has risen rapidly in recent years, according to a new University… read more.
A new UK drug approval pathway, designed to speed up the availability of new medicines, benefits industry over patients and the NHS, argues an expert in The BMJ today. The… read more.
New long-term data from Eli Lilly and Company showed Omvoh (mirikizumab-mrkz) delivered durable efficacy through three years in adults with moderately to severely active Crohn’s disease. These data… read more.
A research team co-led by investigators at Mass General Brigham and the Broad Institute of MIT and Harvard has developed and validated an artificial intelligence model, known as ECG2Stroke, that… read more.
New research presented at this year’s European Congress on Obesity in Istanbul, Turkey (12-15 May) shows that higher body mass index (BMI) is associated with more financial problems,… read more.
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved the medicine Enflonsia (clesrovimab-cfor) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in newborns… read more.
Breeding programs could alter heritable dog characteristics to reduce the rates of brachycephalic obstructive airway syndrome (BOAS), a breathing disorder common in dogs such as Bulldogs, French Bulldogs… read more.
With three people dead and 11 cases from the recent hantavirus outbreak on a cruise ship, UMD’s internationally renowned expert on airborne viruses, Dr. Don Milton, joins public… read more.
Pfizer Inc. announced positive topline results from the Phase III TALAPRO-3 study of Talzenna (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with Xtandi (enzalutamide), an… read more.
Occupational burnout is a growing threat to care quality, workforce retention and physician well-being. Pregnant and postpartum physicians-in-training are especially at risk, facing stigma, limited support, and physical… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
